Early research (Phase 1)Study completedNCT00001037
What this trial is testing
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 22